NPHC · Nutra Pharma Corp · Insider Trading
Substantial doubt about the company's ability to continue as a going concern.
“As of the date of the filing of this report, we do not believe that our source of cash is adequate for the next 12 months of operation and there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 19, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-08-21 | DEITSCH RIK J |
Director, President, CEO |
Gift↓
|
Series B Preferred Stock
|
12,000,000 |
| 2021-11-15 | DEITSCH RIK J |
Director, President, CEO |
Buy↑
Filing footnotes — Series B Preferred Stock (Direct)
Series B preferred stock have no right of conversion to shares of common stock. Each share of Series B preferred stock is entitled to vote with the Corporation's common stock as a single class on all matters submitted to common stock holders to vote. Each share of Series B Preferred Stock is entitled to one thousand votes per share. 9,000,000 shares of Series B Preferred Stock were issued in satisfaction of corporate debt owed by the Company to Mr. Deitsch pursuant to a resolution adopted by the board of directors of the Company. |
Series B Preferred Stock
|
9,000,000 |
| 2021-11-15 | DEITSCH RIK J |
Director, President, CEO |
Buy↑
Filing footnotes — Series B Preferred Stock (Direct)
Series B preferred stock have no right of conversion to shares of common stock. Each share of Series B preferred stock is entitled to vote with the Corporation's common stock as a single class on all matters submitted to common stock holders to vote. Each share of Series B Preferred Stock is entitled to one thousand votes per share. 3,000,000 shares of Series A Preferred Stock held by Mr. Deitsch were exchanged for an equal number of Series B Preferred Stock of the Company pursuant to a share exchange agreement between Rik Deitsch and the Company. |
Series B Preferred Stock
|
3,000,000 |